Ruxolitinib, Drugs Monitor

(20 Apr 2021) Ruxolitinib- may be an alternative anti-cytokine therapy

April 30, 2021

Ruxolitinib versus Dexamethasone in Hospitalized Adults with Covid-19: multicenter matched-controlled study https://www.medrxiv.org/content/10.1101/2021.04.20.21255662v1 NCT04337359-Ruxolitinib treatment in the general cohort of patients was associated with equivalent to dexamethasone mortality rate: 9,6% (95% CI 4,6-14,6%) vs 13,0% (95% CI 7,5-18,5%, superiority p=0.35, non-inferiority… Continue reading "(20 Apr 2021) Ruxolitinib- may be an alternative anti-cytokine therapy"

(07 Jan 2021) Ruxolitinib- was associated with significant reduction of biomarkers of inflammation

January 14, 2021

Compassionate use of Ruxolitinib in patients with SarsCov-2 infection not on mechanical ventilation. Short-term effects on inflammation and ventilation https://doi.org/10.1111/cts.12971 Ruxolitinib was provided as a compassionate use in patients consecutively admitted to our institution for Sars-CoV-2 infection. Inclusion criteria were… Continue reading "(07 Jan 2021) Ruxolitinib- was associated with significant reduction of biomarkers of inflammation"

(28 Aug 2020) Ruxolinitib- after 48 h of ruxolitinib treatment 16/18 patients showed evident clinical improvement

August 29, 2020

Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol https://doi.org/10.3389/fmed.2020.00466 Data collection shows a rapid clinical response with no evolution from non-invasive ventilation to mechanical ventilation in 16/18 patients and no response in… Continue reading "(28 Aug 2020) Ruxolinitib- after 48 h of ruxolitinib treatment 16/18 patients showed evident clinical improvement"

(30 May 2020) Ruxolitinib- 90% patients from the ruxolitinib group showed CT improvement at D14

June 1, 2020

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial https://doi.org/10.1016/j.jaci.2020.05.019 Authors conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe COVID-19 (ChiCTR-OPN-2000029580). Forty-three patients were randomly assigned (1:1) to… Continue reading "(30 May 2020) Ruxolitinib- 90% patients from the ruxolitinib group showed CT improvement at D14"

Tag: Ruxolitinib

(20 Apr 2021) Ruxolitinib- may be an alternative anti-cytokine therapy

(07 Jan 2021) Ruxolitinib- was associated with significant reduction of biomarkers of inflammation

(28 Aug 2020) Ruxolinitib- after 48 h of ruxolitinib treatment 16/18 patients showed evident clinical improvement

(30 May 2020) Ruxolitinib- 90% patients from the ruxolitinib group showed CT improvement at D14